Caribou Biosciences (CRBU) Stock Analysis & AI Equity Report
Caribou Biosciences (CRBU) overview
Caribou Biosciences (CRBU) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 11.2m and operating profit of USD -148m; the year-end share price was 1.59 USD and market capitalisation was USD 151m. Caribou Biosciences is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Caribou Biosciences's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Caribou Biosciences
Caribou Biosciences is a clinical-stage biopharmaceutical company developing genome-edited cell therapies. Its chRDNA technology is used to engineer allogeneic, or off-the-shelf, CAR-T cell therapy candidates made from healthy donor cells. The company is advancing candidates targeting CD19 for B-cell non-Hodgkin lymphoma and BCMA for multiple myeloma. These investigational therapies are intended for patients with hematologic malignancies and are being evaluated in clinical trials.
Generate the Caribou Biosciences report
Caribou Biosciences is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Caribou Biosciences and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Caribou Biosciences
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.